CO2 laser treatment for regional cutaneous malignant melanoma metastases

Dermatologic Surgery

Volumn 41, Issue 1, 2015, Pages 78-82

  Van Jarwaarde, Jorien A ^a   Wessels, Ronnie ^a   Nieweg, Omgo E ^a   Wouters, Michel W J M ^a   Van Der Hage, Jos A ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CARBON DIOXIDE LASER; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CUTANEOUS MELANOMA; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; IN-TRANSIT METASTASIS; LASER SURGERY; LIMB PERFUSION; MALE; MELANOMA METASTASIS; MORBIDITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REGIONAL METASTASIS; RETROSPECTIVE STUDY; SATELLITE METASTASIS; SKIN DEFECT; THERAPY EFFECT; TREATMENT DURATION; WOUND INFECTION; GAS LASER; MELANOMA; MIDDLE AGED; PATHOLOGY; SECONDARY; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LASERS, GAS; MALE; MELANOMA; MIDDLE AGED; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84920815606     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1097/DSS.0000000000000251     Document Type: Article

References (13)

1. Francken AB, Bastiaannet E, Hoekstra HJ. Follow-up in patients with localised primary cutaneous melanoma. Lancet Oncol 2005;6:608-21.
2. Hayes AJ, Clark MA, Harries M, Thomas JM. Management of in-transit metastases from cutaneous malignant melanoma. Br J Surg 2004;91:673-82.
3. Strobbe LJ, Nieweg OE, Kroon BBR. Carbon dioxide laser for cutaneous melanoma metastases: indications and limitations. Eur J Surg Oncol 1997;23:435-8.
4. Gibson SC, Byrne DS, McKay AJ. Ten-year experience of carbon dioxide laser ablation as treatment for cutaneous recurrence of malignant melanoma. Br J Surg 2004;91:893-5.
5. Kaplan I, Ger R, Sharon U. The carbon dioxide laser in plastic surgery. Br J Plast Surg 1973;26:359-62.
6. Hill S, Thomas JM. Use of carbon dioxide laser to manage cutaneous metastases from malignant melanoma. Br J Surg 1996;83:509-12.
7. Gimbel MI, Delman KA, Zager JS. Therapy for unresectable recurrent and in-transit extremity melanoma. Cancer Control 2008;15:225-32.
8. Thompson JF, Hunt JA, Shannon KF, Kam PC. Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg 1997;132:903-7.
9. Noorda EM, Vrouenraets BC, Nieweg OE, van Geel AN, et al. Safety and efficacy of isolated limb perfusion in elderly melanoma patients. Ann Surg Oncol 2002;9:968-74.
10. Hoekstra HJ. The European approach to in-transit melanoma lesions. Int J Hyperthermia 2008;24:227-37.
11. Testori A, Faries MB, Thompson JF, Pennacchioli E, et al. Local and intralesional therapy of in-transit melanoma metastases. J Surg Oncol 2011;104:391-6.
12. Sasse AD, Sasse EC, Clark LG, Ulloa L, et al. Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database Syst Rev 2007:CD005413.
13. Chapman PB, Hauschild A, Robert C, Haanen JB, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.